THE RISK OF THE DEVELOPMENT TYPE 1 DIABETES MELLITUS: IMMUNOLOGIC AND HORMONAL MARKERS

W. Mlynarski, K. Wyka, W. Andrzejewski, **B. Mianowska**, J. Bodalski *Institute of Paediatrics, Medical University of Lodz, Poland* <u>kwyka@alef.am.lodz.pl</u>

The clinical manifestation of type 1 diabetes mellitus preface by the long term prediabetes stage, characterising by occurrence of anti-islet antibodies and insulin secretion disturbance. The aim of this study was evaluate the risk of type 1 diabetes mellitus among the children possesses the antiislet immune markers (ICA, anti-GAD, IA2, IAA) and determine prognostic sense of the Cpeptide's (Cp) level evaluation. From 88 children in prediabetic stage (Me of the observation time 52months.), have been selected 8(9.1%) kids (mean of age10.5±8.9) in case which the clinical symptoms of type 1 diabetes mellitus appears during the observation (mean 30 months). The ICA were determined by indirect immunofluorescence, anti-GAD, IA2 and by RIP. The level of Cpeptide was estimated by radioimmunoassay. Presence of all kinds of antibodies was found in 37.5%(3/6). Three antibodies types (except IAA) were detected in 25%(2/8). The antibodies pairs: ICA/anti-GAD alsoICA/IA2 were found in two cases. There was no any antibodies presence in case of one. The analysis by Kaplan-Meier method showed the pEFS=0.55 after 92 months of observation. There were differences in C-peptide levels between group of children with IDDM and all other children (0,34vs0.67pmol/ml,p<0.001). This fact let to calculate the hormone level lower below that the risk of type 1 diabetes mellitus development dramatically increase. By ROC method the boundary level of C-peptide on 0.45pmol/ml was established. In prediabetic stage increasing humoral reaction and lower concentration of C-peptide precede the clinical manifestation of the type 1 diabetes mellitus.

Supported by Ministry of Health no 16/eks/7/2002